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A cancer staging system should be explicit, practical, and should pro-
vide information required tomake important decisions about prognosis
and treatment. The ﬁrst FIGO staging nomenclatures for gynecologic
cancers were based solely on the anatomical extent of the disease
determined by physical examination and a few surgical parameters.
As surgical evaluation of some gynecologic cancers became feasible,
the FIGO staging system was revised to include surgical and histopath-
ologic assessment of the tumor for most gynecologic cancers. Despite
modiﬁcations in staging systems, the principles and purpose of cancer
staging remain the same (Box 1).
Identiﬁcation of the cellular events leading to carcinogenesis pro-
vides additional information for comprehensive tumor classiﬁcation
and prognostication. While genetic sequencing was expensive and
identifying driver mutations was laborious in the past, current technol-
ogies produce high-throughput data that makes methodical analysis of
DNA, RNA, and proteins achievable. Genetic and molecular studies can
be performed on blood and tumor samples obtained during the opera-
tive evaluation and treatment of cancer. A classiﬁcation based on geno-
mic and proteomic platforms is practical at this time, has minimal
morbidity, and could provide essential information regarding prognosis
and response to targeted therapies. The present article focuses on mo-
lecular discoveries that have been made in the last decade that should
be considered in future revisions of gynecologic cancer staging systems.
2. Ovarian cancer
2.1. Classiﬁcation
Shih and Kurman [1] classiﬁed ovarian cancers into two types based
on genetic and histologic features. Type I is a heterogeneous group
including low-grade serous, endometrioid, clear-cell, and mucinous
carcinomas, which commonly arise from precursor lesions and are
typically slow growing. Type II includes high-grade serous cancers,
which usually present with advanced stage and metastasis at the time
of diagnosis and are associated with p53mutations. Prat et al. [2] pro-
posed a ﬁve-subtype classiﬁcation including high-grade serous
(HGSOv), low-grade serous (LGSOv), endometrioid (EOv), clear-cell
(CCOv), and mucinous (MOv) carcinomas. Each subtype has distinct
molecular events leading to carcinogenesis, therefore resulting in differ-
ent precursor lesions, patterns of spread, prognosis, and response tohttp://dx.doi.org/10.1016/j.ijgo.2015.06.009
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).adjuvant therapy. Morphologic assessment is currently the mainstay
for subtype diagnosis, but immunohistochemical reactivity to Wilms
tumor protein (WT-1), estrogen receptor (ER), hepatocyte nuclear
factor (HNF) 1β, cancer antigen 125 (CA-125), and Ki-67 (Table 1)
may be helpful [3]. Since research to detect aberrations in molecular
pathways is gaining popularity, characteristic genetic proﬁles for each
subtype have also been determined (Table 1). Since there is overlap in
the histologic features and genetic proﬁles of different ovarian cancer
subtypes, there is no clear consensus on which tests to routinely
perform for accurate diagnosis.
2.2. Homologous recombination repair pathway
Germline and somatic mutations in tumor suppressor genes BRCA1
and BRCA2 disrupt the cell’s ability to repair double strand breaks in
damaged DNA (homologous recombination). The BRCA pathway is
disabled in up to 50% of HGSOv. An assessment of 390 ovarian cancers
showed similar mutation rates in HGSOv and non-HGSOv of 13 genes
involved in homologous recombination DNA repair. The presence of a
mutation was associated with a longer overall survival and improved
response to platinum-based chemotherapy [4]. Poly (ADP-ribose) poly-
merase (PARP) inhibitors induce double strand DNA breaks that lead to
genomic instability and death in cells that lack homologous recombina-
tion repair genes. This treatment is therefore being used to target BRCA1
and BRCA2 mutated tumors [5]. Determination of BRCA status is
consequently valuable and satisﬁes the principles of cancer staging
since it classiﬁes patients into different prognostic groups and predicts
response to chemotherapy and targeted PARP inhibitors.
2.3. KRAS/MAPK pathway
The characteristic genetic alterations in the LGSOv subtype are
mutations in oncogenes KRAS and BRAF, leading to activation of the
mitogen-activated protein kinase (MAPK) pathway [3]. Although
LGSOv tend to be less aggressive, they are relatively non-responsive to
platinum-based chemotherapy. MEK inhibitors down-regulate key
enzymes in the MAPK pathway and therefore show promise in the
treatment of LGSOv and other tumors with MAPK pathway aberrations.
Pre-clinical research and multiple clinical trials have evaluated the use
of MEK inhibitors in ovarian and other gynecologic malignancies [6]. It
is important to identify cancers with MAPK pathway abnormalities asGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Box 1
The purpose of cancer staging.
• To develop an accurate and universal terminology to describe
the extent of disease.
• To characterize patients with cancer into different prognostic
groups and enable clinicians to counsel patients about treatment
options, morbidities, and mortality.
• To allow meaningful comparisons of treatment efficacy and sur-
vival outcomes when comparing treatment strategies, institu-
tions, or geographical areas as part of clinical trials and research.
Table 2
Key mutations and useful biomarkers in the classiﬁcation of endometrial cancer subtype.
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targeted therapies.
2.4. Vascular endothelial growth factor
Angiogenesis is important and necessary for cancer growth and
metastasis. The presence of vascular endothelial growth factor (VEGF)
receptors and ligands has not been associated with prognosis or clinical
outcomes in ovarian cancer. However, bevacizumab, amonoclonal anti-
body that inactivates VEGF has beenwell studied and is important in the
treatment of primary and recurrent ovarian cancer. While the entire
cohort of patients treated with chemotherapy and bevacizumab for pri-
mary ovarian cancer only had a modest improvement in progression-
free survival compared with the patients treated with chemotherapy
alone, Gourley et al. [7] developed a 63-gene signature biomarker to
distinguish bevacizumab responders from non-responders. Preclinical
research has studied the beneﬁt of low-dose VEGFR2 antibodies in
modulating the tumor microenvironment to allow for an immune-
stimulatory phenotype with improved inﬁltration of CD8+ T-cells [8].
Now low-dose bevacizumab is being evaluated in combination with
cancer vaccine therapies for breast and ovarian cancer. The search for
biomarkers to help guide treatment with antiangiogenesis drugs is on-
going [9]. Appropriate identiﬁcation of patients that will beneﬁt from
this targeted therapy is vital to the safe and effective use of this expen-
sive and potentially toxic therapy.
2.5. Cancer stem-cell markers
Despite high initial response rates to cytotoxic chemotherapy, the
recurrence rate for ovarian cancer remains high. Themolecular features
of these cancers that lead to recurrence are not clearly understood, but
one theory is the presence of cancer stem cells in the original tumor.
Although cancer stem cells only represent a small proportion of the
tumor, they are resistant to chemotherapy and can grow rapidly, there-
by repopulating tumors and leading to recurrence that is often resistant
to previous chemotherapy. The detection of sensitive markers for
ovarian cancer stem cells would have implications in predicting risk of
recurrence and prognosis. Cell surface receptors such as CD44, CD117,Table 1
Immunohistochemistry reactivity and geneticmutation proﬁle of ovarian cancer subtypes.
Subtype IHC reactivity Genetic mutation proﬁle
HGSOv P53+, WT-1+, ER+,
high Ki-67 index
p53, BRCA1/2, aneuploidy
LGSOv P53-, WT-1+, ER+, low Ki-67 index BRAF and KRASmutations
EOv WT-1-, ER+ ARID1A, CTNNB1, PTEN,
microsatellite instability
CCOv HNF1β+, WT-1-, ER- ARID1A, PIK3CA, PTEN, KRAS
MOv CK7+, CK20+/−, CEA+/−,
CA19-9+/−, CDX2+/−
KRAS, Her2
Abbreviations: HGSOv, high-grade serous ovarian cancer; LGSOv, low-grade serous ovar-
ian cancer; EOv, endometrioid ovarian cancer; CCOv, clear-cell ovarian cancer; MOv,
mucinous ovarian cancer.and CD133 are being evaluated as markers for ovarian cancer stemness
and as targets for therapeutics options against these chemo-resistant
cell types [10]. Identifying cancer stem cells could be very helpful in
predicting response to therapy and tumor behavior.
2.6. Genetic proﬁling in ovarian cancer
The Cancer Genome Atlas (TCGA) research network performed
mRNA analysis on 489 HGSOv cancers and noted p53 mutations in
96% of cases [11]. While p53 is pivotal in HGSOv cancers, it is important
to note that not all p53 mutations are the same and further research
needs to be performed to determine the prognosis of different muta-
tions in the p53 pathway. Anti-mutant p53 drugs are now available
and their ability to restore wild-type p53 properties to p53mutant can-
cers is being studied [12]. In the future, determination of p53mutation
and type should be fruitful in determining prognosis and possibly
response to anti-mutant p53 therapy. Results from the TCGAHGSOv co-
hort are also being used to develop genetic and promoter methylation
proﬁles for chemotherapy responders versus non-responders [13].
Proﬁling of large cohorts of ovarian cancers based on genomic and
proteomic platforms is still required to determine the prognostic ability
of different p53mutations and other genes that are mutated at a lower
but signiﬁcant frequency.
3. Endometrial cancer
3.1. Classiﬁcation
The ﬁrst description of endometrial cancer subtypes was by
Bokhman in 1983 [14]. He distinguished between type I and type II en-
dometrial cancer based on patient phenotype, tumor histology, clinical
behavior, and survival rates. Today, pathologists assign a histologic
type to type I (low-grade endometrioid) and type II (high-grade
endometrioid, serous, clear cell, or carcinosarcoma) endometrial cancer
based on tumor morphology and a tumor grade (1: well differentiated;
2: moderately well differentiated; or 3: poorly differentiated), based on
glandular architecture and nuclear grade. Through genetic proﬁling of
different histologic types, we now know that these tumors differ in
the early driver mutations that lead to carcinogenesis. The key muta-
tions responsible for carcinogenesis are different in endometrioid endo-
metrial cancers (EECs) and non-EECs (serous carcinomas and clear-cell
carcinomas [CCCs]) (Table 2), although there may be some overlap
in genetic proﬁles since progression from endometrioid to non-
endometrioid carcinoma may occur [15].
In addition to a high frequency of mutations in PTEN, CTNNB1, KRAS,
FGFR-2, ARID1A, and PIK3CA, EECs often express estrogen and progester-
one receptors and have microsatellite instability. The presentation,
clinical behavior, and prognosis of EECs differ dependent on tumorHistologic type Biomarker Mechanism Frequency
Endometrioid PTEN Mutation/deletion 50%−80%
EGFR Overexpression 40%−45%
KRAS Mutation 10%−40%
CTNNB1 Mutation 10%−45%
FGFR2 Mutation 16%
MLH1 Promoter methylation 20%
Serous TP53 Mutation/overexpression 80%−90%
HER2/neu Ampliﬁcation/overexpression 30%−40%
PIK3CA Ampliﬁcation 45%
E-cadherin Loss of function 40%−90%
EGFR Overexpression 35%−60%
Clear cell PIK3CA Mutation
PTEN Mutation
ARID1A Mutation/loss of function
HNF1β Overexpression
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have signiﬁcant overlap with serous carcinomas. Whereas low-grade
EECs have a higher frequency of PTEN, KRAS, and CTNNB1 (beta-catenin)
mutations, high-grade EECs often have p53 and PIK3CAmutations [3,15].
Now we will discuss a few of the targetable pathways involved in endo-
metrial carcinogenesis and associated targeted therapies (Table 3).
3.2. PTEN-PI3K-AKT-mTOR pathway
Mutations in the tumor suppressor gene PTEN and oncogene PIK3CA
lead to direct activation of the anti-apoptotic PI3K-AKT pathway. PTEN
mutations are more commonly seen in low-grade EECs, but loss of
PTEN protein expression can lead to up-regulation of the PI3K-AKT
pathway and inhibition of apoptosis, which is a poor prognostic maker
in EECs [15]. PIK3CA mutations are more common in high-grade EECs
and mixed histology endometrial cancers. PI3K/AKT/mTOR inhibitors
are being evaluated in pre-clinical and clinical trials [16]. While the
results of single therapy mTOR inhibitors in phase II trials have been
modest, there seems to be more potential when used in combination
with chemotherapy or other targeted inhibitors of angiogenesis or the
MAPK pathways. Unfortunately, the response to treatment with PI3K-,
AKT-, or mTOR-inhibitors does not correlate with PTEN mutations or
phosphorylated downstream targets (AKT, mTOR, S6). Therefore, we
must continue to search for biomarkers that predict response to these
targeted therapies.
3.3. KRAS-MAPK pathway
Mutated KRAS GTPase protein up-regulates the MAPK pathway
and can also bind the PIK3CA protein leading to activation of the PI3K-
AKT-mTOR pathway. KRAS mutations are mostly seen in EECS, rarely
in non-EECs, and are associated with longer disease-free survival [17].
Pre-clinical trials ofMEK inhibitors as single therapy and in combination
with PI3K/AKT/mTOR inhibitors are promising and a clinical trial
evaluating the response of the MEK inhibitor trametinib alone or in
combination with an AKT inhibitor is underway.
3.4. Tyrosine kinase receptors
Tyrosine kinase receptors (TKRs) are a family of transmembrane gly-
coproteins that are usually activated by a variety of growth factors. The
important TKRs involved in endometrial carcinogenesis include HER2
(Erb-B2), EGFR (Erb-B1), FGFR2, and VEGFR.Table 3
Targeted therapies in treatment of endometrial cancer.
Target Drug Research status
PI3K GDC-0941 Preclinical
AKT GSK2141795 Phase II active
mTOR Temsirolimus Phase II completed
Everolimus Phase II completed
Ridaforolimus Phase II completed
AZD8055 Preclinical
PI3K/mTOR GDC-0980 Preclinical
MEK Trametinib Phase II active
PD98059 Preclinical
PD0325901 Preclinical
HER2 Trastuzumab Phase II completed and active
Pertuzumab Phase II completed
EGFR Erlotinib Phase II completed
Geﬁtinib Phase II completed
Pertuzumab Phase II completed
HER2/EGFR Lapatinib Phase II completed
FGFR2 Ponatinib Phase I active
PD173074 Preclinical
VEGF Bevacizumab Phase II completed and active
FGFR2/VEGF Brivanib Phase II completed
Nintedanib Phase II completed3.4.1. HER2
Overexpression of the HER2/neu protein is common in uterine
papillary serous cancers (UPSCs) and leads to cell proliferation, differen-
tiation, and migration by activation of both the PI3K-AKT-mTOR and
MAPK pathways. HER2/neu RNA ampliﬁcation and protein overexpres-
sion are ideal biomarkers as they predict survival and response to
chemotherapy as well as PI3K and mTOR inhibitors [18]. Trastuzumab
and pertuzumab are monoclonal antibodies against HER2 receptors
that are approved for the treatment of HER2-positive breast cancer.
They are currently being evaluated in the treatment of HER2-positive
UPSCs.
3.4.2. Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) overexpression is seen in
both EECs (low-grade and high-grade) and UPSCs [18]. EGFR activation
leads to the activation of many cellular pathways including PI3K-AKT-
mTOR and MAPK pathways. EGFR inhibitors geﬁtinib and erlotinib did
not improve survival in phase II trials of advanced endometrial cancer
and response rates were not associated with EGFR overexpression
[19]. Translational studies of the lapatinib (dual EGFR and HER
inhibitor) phase II trial identiﬁed one previous unreported EGFR muta-
tion that was present and associated with objective tumor response in
one patient [20]. Further studies need to be performed to validate the
value of this mutation in predicting response to lapatinib.
3.4.3. FGFR2
Mutations in this oncogene are more common in low-grade EECs,
but it is associated with chemo-resistance and with poor progression-
free survival and overall survival [17]. Pre-clinical studies show that
the FGFR2 inhibitor PD173074 has a synergistic effect on apoptosis
when combined with cytotoxic chemotherapy [19]. In phase II clinical
trials, treatment of recurrent endometrial cancer with brivanib or
nintedanib resulted in a progression-free interval of at least 6 months
in 30% and 22% of patients, respectively [21,22].
3.4.4. Vascular endothelial growth factor
Aswith ovarian cancer, there is no clear consensus onwhether VEGF
overexpression is associatedwith prognosis or response to angiogenesis
inhibitors in endometrial cancer. While bevacizumab alone had a mod-
est response rate in recurrent endometrial cancer, the combinationwith
mTOR inhibitor temsirolimus improved response rates but was also
more toxic [23]. The efﬁcacy and toxicity of bevacizumabwith cytotoxic
chemotherapy for advanced endometrial cancer is being evaluated in
phase II trials. Since combination treatments can be expensive and
toxic, it is important to focus future research on biomarkers that predict
response to antiangiogenic drugs so that this treatment can be limited
to patients who would beneﬁt from treatment.
3.5. Genetic proﬁling in endometrial cancer
The 2013 TCGA cooperative study on endometrial carcinoma has
expanded the dualistic clinicopathologic classiﬁcation (types I and II)
to four molecular genetic categories: (1) POLE ultramutated; (2) micro-
satellite instability hypermutated, corresponding to type I; (3) copy-
number low (CTNNB1mutated); and (4) copy-number high (TP53mu-
tated), corresponding to type II [24]. Although categories 2 and 3
included mainly EECs and category 4 had predominantly serous
carcinomas, 25% of high-grade EECs showed a genetic proﬁle similar
to serous carcinomas and were re-classiﬁed. Despite overlapping of
the molecular genetic ﬁndings, there was some association between
separate categories and prognosis. The novel POLE ultramutated catego-
ry consisted of 7% of tumors (type I and type II) and was characterized
by mutations in the gene POLE that is important for DNA replication
and repair. POLEmutations predicted favorable prognosis, particularly
in high-grade tumors. In another endometrial cancer cohort of 535
EECs, POLE mutations were found in 5.6% (70% were high-grade EEC)
Table 4
Important biomarkers and predictive ability in cervical cancer.
Predictive value Biomarkers
Associated with prognosis HIF-1α
VEGF
SCC Ag
CEA
HR-HPV and type
Associated with chemotherapy sensitivity HIF-1α
EGFR
CD44v6
Associated with radiosensitivity COX-2
HIF-2α
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stability genotypes [25]. Therefore, classiﬁcation as POLE ultramutated
provides information regarding prognosis and would preclude the
need for Lynch screening in these tumors.
4. Cervical cancer
Among gynecologic malignancies, cervical cancer has the highest in-
cidence andmortality rate worldwide. Numerous biomarkers are under
investigation to predict progression of pre-invasive lesions to invasive
disease, as well as to predict prognosis and response to treatment of
invasive cervical cancer.
4.1. Proliferation markers
Proliferation markers such as p16, p53, and Ki-67 index are seen in
advanced stage andmetastatic disease but they are not proven indepen-
dent predictors of survival since almost all these patients will succumb
to their disease. However, the presence of p16 andKi-67 by immunohis-
tochemistry had a higher sensitivity and speciﬁcity in detecting clinical-
ly signiﬁcant pre-invasive lesions (CIN2, CIN3, and adenocarcinoma in
situ) than high-risk HPV testing [26]. IHC for p16 and Ki-67 may be
incorporated into cervical cancer screening to identify and treat pre-
invasive lesions that are likely to progress to invasive disease.
4.2. Biomarkers predicting advanced disease and prognosis
High expression of angiogenesis markers like HIF-1α and VEGF are
associated with poor prognosis in cervical cancer. HIF-1α expression
allows the proliferation and metastasis of cancer cells in an oxygen-
and nutrient-poor environment, and high IHC reactivity to HIF-1α
predicts lower survival in cervical squamous cell carcinoma (SCC) and
adenocarcinomas. VEGF expression has been correlated to lymph node
metastasis and poor survival [27]. While most cervical cancers are pos-
itive for HRHPV, HPV-negative status was associated with an increased
risk of recurrence and death [28]. A high level of the serum biomarker
SCC antigen correlates with lymph node metastasis and advanced
disease visible by FDG-PET imaging and this information may guide
treatment strategies for individual patients [29].
4.3. Biomarkers predicting response to therapy
Hypoxic tumor environments prevent degradation of HIF-1α pro-
teins and also increase resistance to chemotherapy and radiation [27].
Therefore HIF-1α expression may be a marker of resistance to primary
chemo-radiation therapy, but further research needs to be conducted
to validate this theory. In a systematic review, IHC reactivity to EGFR/
HER2 and COX-2 was associated with resistance to chemo- and/or
radiation-therapy [30]. Two large cohorts showed EGFR overexpression
and co-expression of EGFR and HER2 was associated with poor
progression-free survival and overall survival in patients treated with
primary chemoradiation therapy. COX-2 is associated with angiogene-
sis, inhibition of apoptosis, and resistance to radiation therapy. This
makes COX-2 an attractive target and preclinical studies already show
that COX-2 inhibition improves cervical cancer response to radiation.
4.4. Future of biomarkers in cervical cancer
Biomarkers such as high-risk HPV testing and IHC for p16 and Ki-67
index score have been tested in large cohorts and will soon be imple-
mented in guidelines for screening and treating pre-invasive lesions.
Many biomarkers have shown promise in predicting the risk of
recurrence and response to chemo- and radiation-therapy (Table 4)
but they have notmoved into clinical practice because of the lack of pro-
spective data with large cohorts. Future research should be focused on
validating the prognostic values of candidate biomarkers including cellcycle regulators (p16, p21, p27, cyclin A/D/E), receptor tyrosine kinases
(EGFR, HER2), metastatic or stem cell markers (CD44, cathepsin D), and
apoptotic markers (p53, Bcl-2, Bax) [30].
5. Vulvar cancer
Accurate evaluation of the prognostic potential of biomarkers in
vulvar cancer is difﬁcult because most studies involve small case series.
Biomarkers evaluated in SCC of the cervix have also been evaluated in
small series of vulvar cancer. Similar to cervical SCC, biomarkers p16,
p21, VEGF, CD44, EGFR, and HER2 may correlate to clinical outcomes
in vulvar SCC [31]. High VEGF expression was associated with poor sur-
vival outcome in a series of 25 vulvar cancers, however multivariate
analysis was not performed owing to the small size of the cohort [32].
Clinical trials evaluating treatment of antiangiogenesis drugs and
other targeted therapies are also difﬁcult owing to the low incidence
of disease.
Unlike cervical cancer, multiple small studies report conﬂicting data
about the association of high-risk HPV and prognosis of vulvar cancers.
Most of the data does not show a signiﬁcant association between HPV
and prognosis, while another reports favorable clinical outcomes in
HPV positive vulvar cancers when compared with HPV-negative vulvar
cancers [31].
Matrix metalloproteinase 2 (MMP-2) is a protein biomarker present
in approximately 50% of vulvar cancers and the degree of IHC reactivity
is higher in invasive carcinomaswhen comparedwith pre-invasive pre-
cursor lesions [33]. IHC reactivity ofMMP-2was associatedwith shorter
survival after adjusting for tumor size, depth of invasion, and patient age
in a multivariate analysis of 75 vulvar cancers [34]. When MMP-2 ex-
pression exceeded 50%, there was a signiﬁcant reduction in ﬁve-year
overall survival from72.3% to 40%. Nafamostatmesilate is a synthetic in-
hibitor of MMP-2 that was evaluated in preclinical studies of SCC of the
vulva and the head and neck [35]. Nafamostat decreased proliferation
rates in vulvar cancer cell lines but it did not cause cell death and did
not reduce tumor burden in tumor-bearing mice.
6. Conclusion
Considerable progress has been made in the identiﬁcation and vali-
dation of molecular markers for gynecologic cancers in the past decade.
However, this progress has not been accompanied by the introduction
of universal molecular marker testing in clinical practice. Genomic and
proteomic proﬁling of large cohorts of gynecologic cancerswill generate
a large amount of data regarding early mutation events in carcinogene-
sis. Now, expert committees need to be assembled to reach a consensus
on which biomarkers should be incorporated into classiﬁcation and
staging of gynecologic cancers.
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